In recent months the UK External Innovation team at Eisai Hatfield Research Laboratories in Hatfield has been exploring partnerships and opportunities to further innovate in the lifesciences sector and in signing up to the Milner Therapeutics Consortium we join eight other pharmaceutical companies and three research academic centres who are striving for excellence in this field.

The agreement with the Milner Therapeutics Consortium is designed to facilitate the speedy exchange of reagents and information for research collaboration with academics across the Cambridge region. Each industry partner has set aside funds for collaborative projects, which are open to any therapeutic area and are expected to lead to joint publications.

Post Navigation